Top Markets
Coin of the day
Hemostemix Inc. Hemostemix Inc.

Hemostemix Inc.

HEM
Rang in Aktien #32158
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Aktienkurs
$0.05504527
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$10.89M
Veränderung (1 Tag)
15.38%
Veränderung (1 Jahr)
-10.64%
Land
CA
Handel Hemostemix Inc. (HEM)

Kategorie

Kursverlauf für Hemostemix Inc. (HEM)
Höchster Schlusskurs: $0.05 am 2026-08-01

Niedrigster Schlusskurs: $13.17 am 2014-11-01
Kursverlauf der Aktie von Hemostemix Inc. von 2014 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) -3.76%
2025 16.47%
2024 0.85%
2023 -52.75%
2022 -7.37%
2021 -60.16%
2020 105.00%
2019 -89.61%
2018 12.43%
2017 -27.92%
2016 -79.94%
2015 -39.73%
2014 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$515.58 32.24%
US
$992.01 50.00%
NL
$110.53 -37.27%
AU
$736.64 6.99%
CH
$1.06K -6.67%
KR